Celea Therapeutics to present Phase 3 IPF trial data at ERS Congress

August 25, 2026 7:00 AM

Celea Therapeutics, Inc. will present data from its deupirfenidone (LYT-100) program at the European Respiratory Society Congress in Barcelona, Spain ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found